Clinuvel To Build Vitiligo Pipeline And Commercial Presence
This article was originally published in The Pink Sheet Daily
Following EU approval last year of its lead sunlight-intolerance product Scenesse, the rare dermatological disease biotech has turned to developing its vitiligo pipeline.
You may also be interested in...
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.